Piotr Cierpikowski1, Anna Lis-Nawara2, Pawel Gajdzis3, Julia Bar2. 1. Department of Immunopathology and Molecular Biology, Wroclaw Medical University, Wroclaw, Poland cierpikowski@gmail.com. 2. Department of Immunopathology and Molecular Biology, Wroclaw Medical University, Wroclaw, Poland. 3. Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Wroclaw, Poland.
Abstract
AIM: The purpose of this study was to explore the parallel expression of platelet-derived growth factor receptor α (PDGFRα) and human epidermal growth factor receptor 2 (HER2) or p53 in relation to clinicopathological parameters of oral squamous cell carcinoma (OSCC) to define their role in progressive growth of tumor. MATERIALS AND METHODS: Expression of PDGFRα, HER2 and p53 was evaluated in 71 OSCC samples by immunohistochemistry. HER2 status was verified by fluorescence in situ hybridization. RESULTS: PDGFRα and p53 expression were associated with tumor grade (p=0.043 and p=0.040, respectively). HER2 expression was more frequent in advanced (III/IV) cancer (p=0.006). A positive correlation of PDGFRα with HER2 (r=0.267; p=0.024) and with p53 (r=0.266; p=0.025) was noted. PDGFRα/HER2 and PDGFRα/p53 co-expression was found more often in G3 than in G1 and G2 tumors (p=0.008 and p=0.015, respectively). CONCLUSION: Our study revealed that PDGFRα/HER2 and PDGFRα/p53 co-expression exists in poorly differentiated OSCCs, suggesting that cooperation between these proteins might enhance aggressive behavior of tumor. Copyright
AIM: The purpose of this study was to explore the parallel expression of platelet-derived growth factor receptor α (PDGFRα) and humanepidermal growth factor receptor 2 (HER2) or p53 in relation to clinicopathological parameters of oral squamous cell carcinoma (OSCC) to define their role in progressive growth of tumor. MATERIALS AND METHODS: Expression of PDGFRα, HER2 and p53 was evaluated in 71 OSCC samples by immunohistochemistry. HER2 status was verified by fluorescence in situ hybridization. RESULTS: PDGFRα and p53 expression were associated with tumor grade (p=0.043 and p=0.040, respectively). HER2 expression was more frequent in advanced (III/IV) cancer (p=0.006). A positive correlation of PDGFRα with HER2 (r=0.267; p=0.024) and with p53 (r=0.266; p=0.025) was noted. PDGFRα/HER2 and PDGFRα/p53 co-expression was found more often in G3 than in G1 and G2 tumors (p=0.008 and p=0.015, respectively). CONCLUSION: Our study revealed that PDGFRα/HER2 and PDGFRα/p53 co-expression exists in poorly differentiated OSCCs, suggesting that cooperation between these proteins might enhance aggressive behavior of tumor. Copyright
Authors: Yumna Adnan; Syed Muhammad Adnan Ali; Muhammad Sohail Awan; Romana Idress; Muhammad Ozair Awan; Hasnain Ahmed Farooqui; Hammad Afzal Kayani Journal: PLoS One Date: 2022-05-11 Impact factor: 3.752